Recent advances in the biology and therapy of medullary thyroid carcinoma.

All other mutational subgroups ( RET non-M918T mutation, RAS mutation, RAS wt, RET and RAS wt, RET unknown status, and RET mutation of unknown significance) also exhibited decreased HR in response to cabozantinib treatment; the PFS differences in these subgroups did not reach statistical significance, although in some cases this was likely due to the small size of the subgroups.

also in 111,027 other papers

Tumors were stratified by 111 In-DOTATATE scintigraphy for SSTR expression; in SSTR-positive midgut neuroendocrine tumors (NETs), 177 Lu-DOTATATE (Lutathera) treatment resulted in highly significant prolongation of PFS and OS and modestly increased objective response rate (ORR).

also in 132,142 other papers